Cytosin-Arabinosid
Adult Acute Monoblastic Leukemia (M5a)
Chinese PLA General HospitalPhase 3Active
BBB
78/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 70/ 100
- Competitive Position
- 95/ 100
Competitive context
14 Active assets in the Adult Acute Monoblastic Leukemia (M5a) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE Stanford University | Phase 3 | BBB |
Daunorubicin National Cancer Institute (NCI) | Phase 3 | BBB |
Mitoxantrone Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2/3 | BBB |
Cyclophosphamide ECOG-ACRIN Cancer Research Group | Phase 3 | BBB |
FILGRASTIM Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Cytosin-Arabinosid is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →